ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-05-12 22:05 |
ERYTECH fait le point sur ses activités et publie ses résultats financiers du p…
|
French | 415.5 KB | ||
| 2022-05-12 22:05 |
ERYTECH Provides Business and Financial Update for the First Quarter of 2022
|
English | 378.5 KB | ||
| 2022-04-28 22:05 |
ERYTECH annonce le dépôt de son Document d’Enregistrement Universel 2021 et de …
|
French | 255.6 KB | ||
| 2022-04-28 22:05 |
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annua…
|
English | 216.4 KB | ||
| 2022-04-27 18:53 |
Document d'Enregistrement Universel 2021
|
French | 4.0 MB | ||
| 2022-04-14 08:53 |
Franchissement de seuils
|
French | 205.6 KB | ||
| 2022-04-06 22:05 |
ERYTECH annonce la publication des résultats positifs de l’essai de phase 2 év…
|
French | 293.9 KB | ||
| 2022-04-06 22:05 |
ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial …
|
English | 291.2 KB | ||
| 2022-04-06 19:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 230.2 KB | ||
| 2022-04-06 19:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 208.9 KB | ||
| 2022-04-04 07:30 |
ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the Euro…
|
English | 264.6 KB | ||
| 2022-04-04 07:30 |
ERYTECH présentera une nouvelle approche de vésiculation au 24ème congrès de l…
|
French | 270.3 KB | ||
| 2022-03-28 22:05 |
ERYTECH annonce sa participation à des conférences investisseurs en avril
|
French | 326.7 KB | ||
| 2022-03-28 22:05 |
ERYTECH to Participate in the Upcoming April Investor Conferences
|
English | 320.3 KB | ||
| 2022-03-11 23:18 |
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full …
|
English | 300.1 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
